Lilly Shorts Capitulate as MRK Steals the Week's Spotlight

Eli Lilly and Company enters the back half of August with short sellers continuing to exit at pace — but Tuesday's 1% pullback to $1,233.66 comes on a week when close peer MRK surged 15.7%, making the comparison a touch uncomfortable for LLY bulls.

The clearest story this week is the accelerating retreat of short interest. Bears have now covered aggressively: short interest collapsed 28% in a single session on August 25, dropping to just 0.76% of free float — the lowest reading in the 30-day window by a wide margin and down from around 1.08% flagged in last weekend's stock report. That follows last week's 0.97% reading, itself already a multi-month low after the post-earnings capitulation that began August 5. At this level, short interest is essentially a non-event as a directional signal. It describes an absence of conviction among bears, not any active bullish positioning. The borrow market confirms the same: cost to borrow has more than halved over the past month to 0.23%, and availability is effectively unlimited — there are over 859 million shares available to lend against a short position measured in the single-digit millions. No squeeze pressure exists; no friction for new shorts either.

Options tell a similarly uncrowded story. The put/call ratio has eased to 1.26, essentially flat against its 20-day average of 1.26 — a z-score of nearly zero. That's a notable de-escalation from the 1.34–1.37 range printed in late July and early August, when defensive hedging was more visible. The 52-week PCR range runs from 0.76 to 1.37, so the current reading sits in the upper half but well away from extremes. Options traders are not pressing new bets in either direction.

The Street remains firmly in the bull camp, though the most recent analyst moves have been incremental rather than revelatory. Following the August 5 earnings beat — where the stock jumped 6.8% on the day and extended 9.4% over the following week — Truist raised its target to $1,376 and Wells Fargo lifted to $1,330, both maintaining positive ratings. Cantor Fitzgerald went further, moving to $1,410. Those three actions, all within three weeks of today, collectively push the consensus mean target to $1,315. With the stock at $1,234, that implies roughly 6.5% to the average target — a modest gap for a name this consensus-loved, but it leaves 18 buys in the count with no sells. The factor score on analyst recommendation differential ranks in the 98th percentile versus the broader universe. Valuation remains stretched: the trailing P/E runs at 27x and EV/EBITDA at 22x, though both have compressed slightly over the past 30 days as earnings have grown into the multiple. The ORTEX short score has dropped sharply to 29.3 from 31.4 a week ago, consistent with the covering trend and signalling reduced bearish pressure across all composite inputs.

Insider activity over the past 90 days has been uniformly in one direction: selling. The divisional president sold $7.6 million of stock on August 17 at $1,175. The chief accounting officer sold $2.4 million on August 10. The general counsel sold $6 million on August 7, the day after the earnings-driven spike. Net insider sales over 90 days total approximately $19.3 million. None of these transactions are unusual in size for a $1,200 stock, and significance scores are low across the board — these read as scheduled or opportunistic monetisation following the stock's recovery from the August trough, not a directional call. The Lilly Endowment, the 10.1% anchor holder, trimmed 1.52 million shares as of June 30 but remains the largest single owner by a wide margin.

Against the peer backdrop, MRK's 15.7% weekly surge — likely driven by stock-specific catalysts — makes LLY's flat-to-slightly-positive week look like consolidation rather than weakness. JNJ and NOVN both gained roughly 0.7–2.2% on the week, so LLY's 0.6% advance keeps it broadly in step with the large-cap pharma complex outside of Merck's outlier move. The Q3 earnings date is October 29, giving the stock nine weeks of runway before the next fundamental test. Between now and then, the Foundayo UK commercial ramp and NHS pricing negotiations — flagged in the prior report as a live catalyst — will be the incremental datapoints worth tracking most closely.